Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Editas Medicine, Inc.    EDIT

EDITAS MEDICINE, INC.

(EDIT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Editas Medicine to Participate in Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
09/04/2020 | 08:01am EDT

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

Citi’s 15th Annual BioPharma Virtual Conference
Panel: Innovation in Cell Therapy
Date: Wednesday, September 9, 2020
Time: 3:20 p.m. ET

Wells Fargo 2020 Virtual Healthcare Conference
Fireside Chat
Date: Thursday, September 10, 2020
Time: 10:40 a.m. ET

Morgan Stanley 18th Annual Global Healthcare Conference
Fireside Chat
Date: Tuesday, September 15, 2020
Time: 10:15 a.m. ET

The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor Contact
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com

Media Contact
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about EDITAS MEDICINE, INC.
10/01EDITAS MEDICINE : October 2020 Corporate Presentation
PU
10/01EDITAS MEDICINE : to Participate in Upcoming Investor Conference
AQ
10/01Editas Medicine to Participate in Upcoming Investor Conference
GL
09/28Digital ad demand bounces back for Daily Mirror publisher Reach
RE
09/11EDITAS MEDICINE : Announces U.S. Patent and Trademark Office Grants the Broad In..
AQ
09/11Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad I..
GL
09/09EDITAS MEDICINE : September 2020 Corporate Presentation
PU
09/04Editas Medicine to Participate in Upcoming Investor Conferences
GL
08/24Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for ..
GL
08/07EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
More news
Financials (USD)
Sales 2020 27,6 M - -
Net income 2020 -147 M - -
Net cash 2020 449 M - -
P/E ratio 2020 -13,0x
Yield 2020 -
Capitalization 2 066 M 2 066 M -
EV / Sales 2020 58,7x
EV / Sales 2021 70,1x
Nbr of Employees 208
Free-Float 98,4%
Chart EDITAS MEDICINE, INC.
Duration : Period :
Editas Medicine, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDITAS MEDICINE, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 41,75 $
Last Close Price 33,66 $
Spread / Highest target 93,1%
Spread / Average Target 24,0%
Spread / Lowest Target -16,8%
EPS Revisions
Managers
NameTitle
Cynthia L. Collins President, Chief Executive Officer & Director
James C. Mullen Chairman
Harry R. Gill Senior Vice President-Operations
Michelle Robertson Treasurer, Chief Financial & Accounting Officer
Charles Albright Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
EDITAS MEDICINE, INC.13.00%2 079
LONZA GROUP AG69.31%48 545
SEAGEN INC.75.85%34 961
IQVIA HOLDINGS INC.6.50%31 476
CELLTRION, INC.41.16%30 032
MODERNA, INC.278.02%29 176